Vertidisan PMCF study

Vertidisan PMCF study - VH-90-D PMCF

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00032669

Enrollment

10000

Registered

2025-05-09

Start date

2025-01-10

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

H81

Interventions

Group 1: 1x daily Vertidisan

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Must possess mobile phone or tablet

Exclusion criteria

Exclusion criteria: Musculoskelettal disease including cervical spine disease

Design outcomes

Primary

Measure	Time frame
Endpoint is vertigo improvement measured using the CGI-I inventory after 90 treatment days	—

Secondary

Measure	Time frame
The VSS-sf-VER is used to determine the intensity of dizziness. The DHI is used to measure the dizziness handicap. The CGI-S measures the intensity of the illness.	—

Countries

Germany

Contacts

Public ContactHans-Peter Zenner

Facharztpraxis

hpzenner@hpzenner.de+491709966256

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Aug 10, 2026